Skip to content

The pharmacokinetcs of roflumilast in human

The pharmacokinetcs of roflumilast in human

Status
Recruiting
Phases
Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OPN-15006951
Enrollment
Unknown
Registered
2015-08-21
Start date
2015-08-18
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic obstructive pulmonary disease

Interventions

Healthy subjects:roflumilast

Sponsors

The first hospital of Jilin University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Healthy volunteers; 2. Healthy volunteers between 18 and 40 years of age; 3. body weight >=50kg, and Body Mass Index (BMI) between 19-24kg/m2 with similar weight; 4. No clinically significant laboratory abnormality or other clinical findings indicative of disease (including but not limited to renal, hepatic, gastrointestinal, cardiovascular, neurological disease; 5. Ability to understand and provide written informed consent and voluntary consent to participate in the study.

Exclusion criteria

Exclusion criteria: 1. Clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening(including but not limited to blood pressure,ECG abnormality,a positive hepatitis screen including hepatitis B surface antigen (HBsAg) and hepatitis C/HIV antibody); 2. Drug , alcohol abuse and smoking history in the past year; 3. Participation in another clinical trial within 3 months; 4. Use of any prescription drug therapy within 14 days prior to receiving study drug; 5. A history of hypersensitivity to any drug,especially to roflumilast; 6. Donation or loss of a significant volume of blood or plasma (> 500 mL) within 3 months or intention to donation during study period; 7. A history of postural hypotension; 8. not acceptable of venous puncture sampling; 9. History of difficulties in swallowing; 10. have birth plan within 3 months during or after completing the study; 11. A positive result of pregnancy test; 12. Not able to understand and provide written informed consent and voluntary consent to participate in the study; 13. Consumption of any caffeine-containing foods or beverages within 48 hours prior to receiving study drug; 14. A history of depressive disorder or suicidal tendency.

Design outcomes

Primary

MeasureTime frame
blood pressure;

Countries

China

Contacts

Public ContactCuiyun Li
lcy2442929@126.com+86 13644316966

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026